Prognostic Utility and Characteristics of MIB-1 Labeling Index As a Proliferative Activity Marker in Childhood Low-grade Glioma: a Retrospective Observational Study

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 Apr 5

PMID 38580878

Authors

David Gorodezki

Julian Zipfel

Andrea Bevot

Thomas Nagele

Martin Ebinger

Martin U Schuhmann

Jens Schittenhelm

Affiliations

Soon will be listed here.

Abstract

Purpose: The prognostic utility of MIB-1 labeling index (LI) in pediatric low-grade glioma (PLGG) has not yet conclusively been described. We assess the correlation of MIB-1 LI and tumor growth velocity (TGV), aiming to contribute to the understanding of clinical implications and the predictive value of MIB-1 LI as an indicator of proliferative activity and progression-free survival (PFS) in PLGG.

Methods: MIB-1 LI of a cohort of 172 nonependymal PLGGs were comprehensively characterized. Correlation to TGV, assessed by sequential MRI-based three-dimensional volumetry, and PFS was analyzed.

Results: Mean MIB-1 LI accounted for 2.7% (range: < 1-10) and showed a significant decrease to 1.5% at secondary surgery (p = .0013). A significant difference of MIB-1 LI in different histopathological types and a correlation to tumor volume at diagnosis could be shown. Linear regression analysis showed a correlation between MIB-1 LI and preoperative TGV (R = .55, p < .0001), while correlation to TGV remarkably decreased after incomplete resection (R = .08, p = .013). Log-rank test showed no association of MIB-1 LI and 5-year PFS after incomplete (MIB-1 LI > 1 vs ≤ 1%: 48 vs 46%, p = .73) and gross-total resection (MIB-1 LI > 1 vs ≤ 1%: 89 vs 95%, p = .75).

Conclusion: These data confirm a correlation of MIB-1 LI and radiologically detectable TGV in PLGG for the first time. Compared with preoperative TGV, a crucially decreasing correlation of MIB-1 LI and TGV after surgery may result in limited prognostic capability of MIB-1 LI in PLGG.

Citing Articles

CircMIB1 inhibits glioma development and progression through a competing endogenous RNA interaction network.

Chen S, Li L, Xu W, Xie N, Xu H, Zhou Y Front Mol Biosci. 2024; 11:1513919.

PMID: 39698112 PMC: 11652353. DOI: 10.3389/fmolb.2024.1513919.

Increased Proportion of the Squamous Cell Carcinoma Components Is Associated with Aggressive Behavior and a Worse Prognosis in Resected Pancreatic Adenosquamous Carcinoma.

Tatsuguchi T, Kitahara D, Kozono S, Date K, Shinkawa T, Kuga H J Gastrointest Cancer. 2024; 56(1):5.

PMID: 39422835 DOI: 10.1007/s12029-024-01123-6.

References

Stokland T, Liu J, Ironside J, Ellison D, Taylor R, Robinson K . A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol. 2010; 12(12):1257-68. PMC: 3018938. DOI: 10.1093/neuonc/noq092. View

Gnekow A, Kandels D, Tilburg C, Azizi A, Opocher E, Stokland T . SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma. Klin Padiatr. 2019; 231(3):107-135. DOI: 10.1055/a-0889-8256. View

Jones D, Kieran M, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M . Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2017; 20(2):160-173. PMC: 5786244. DOI: 10.1093/neuonc/nox141. View

Dorward I, Luo J, Perry A, Gutmann D, Mansur D, Rubin J . Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr. 2010; 6(4):346-52. DOI: 10.3171/2010.7.PEDS10129. View

Horbinski C, Hamilton R, Lovell C, Burnham J, Pollack I . Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas. Brain Pathol. 2009; 20(3):581-8. PMC: 8094767. DOI: 10.1111/j.1750-3639.2009.00336.x. View

Tu A, Robison A, Melamed E, Buchanan I, Hariri O, Babu H . Proliferative Index in Pediatric Pilocytic Astrocytoma by Region of Origin and Prediction of Clinical Behavior. Pediatr Neurosurg. 2018; 53(6):395-400. DOI: 10.1159/000490466. View

Hsu C, Ho D, Yang C, Chiang H . Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol. 2003; 16(9):951-7. DOI: 10.1097/01.MP.0000084631.64279.BC. View

Yao R, Cheng A, Zhang Z, Jin B, Yu H . Correlation Between Apparent Diffusion Coefficient and the Ki-67 Proliferation Index in Grading Pediatric Glioma. J Comput Assist Tomogr. 2023; 47(2):322-328. PMC: 10045956. DOI: 10.1097/RCT.0000000000001400. View

Krishnatry R, Zhukova N, Guerreiro Stucklin A, Pole J, Mistry M, Fried I . Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. Cancer. 2016; 122(8):1261-9. DOI: 10.1002/cncr.29907. View

10.

Grzybicki D, Liu Y, Moore S, Brown H, Silverman J, DAmico F . Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer. 2001; 92(10):2720-6. DOI: 10.1002/1097-0142(20011115)92:10<2720::aid-cncr1626>3.0.co;2-z. View

11.

Greuter L, Guzman R, Soleman J . Pediatric and Adult Low-Grade Gliomas: Where Do the Differences Lie?. Children (Basel). 2021; 8(11). PMC: 8624473. DOI: 10.3390/children8111075. View

12.

Krishnan S, Muthiah S, Rao S, Salem S, Madabhushi V, Mahadevan A . Mindbomb Homolog-1 Index in the Prognosis of High-Grade Glioma and Its Clinicopathological Correlation. J Neurosci Rural Pract. 2019; 10(2):185-193. PMC: 6454943. DOI: 10.4103/jnrp.jnrp_374_18. View

13.

Ryall S, Zapotocky M, Fukuoka K, Nobre L, Stucklin A, Bennett J . Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020; 37(4):569-583.e5. PMC: 7169997. DOI: 10.1016/j.ccell.2020.03.011. View

14.

Gerdes J, Schwab U, Lemke H, STEIN H . Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1):13-20. DOI: 10.1002/ijc.2910310104. View

15.

Shaw E, Wisoff J . Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol. 2003; 5(3):153-60. PMC: 1920689. DOI: 10.1215/S1152851702000601. View

16.

Thotakura M, Tirumalasetti N, Krishna R . Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. J Cancer Res Ther. 2014; 10(3):641-5. DOI: 10.4103/0973-1482.139154. View

17.

Ryall S, Tabori U, Hawkins C . Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun. 2020; 8(1):30. PMC: 7066826. DOI: 10.1186/s40478-020-00902-z. View

18.

Rickert C, Paulus W . Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001; 17(9):503-11. DOI: 10.1007/s003810100496. View

19.

Wisoff J, Sanford R, Heier L, Sposto R, Burger P, Yates A . Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery. 2011; 68(6):1548-54. DOI: 10.1227/NEU.0b013e318214a66e. View

20.

Kaluza J, Adamek D, Pyrich M . Ki-67 as a marker of proliferation activity in tumor progression of recurrent gliomas of supratentorial localization. Immunocytochemical quantitative studies. Pol J Pathol. 1997; 48(1):31-6. View